Answers are grounded in this paper and cite their sources.
Purpose Patients with metastatic rhabdomyosarcoma (MTS RMS) and lung as the only metastatic site have better reported outcomes than other patients with MTS RMS. We analysed patients with lung-only MTS RMS receiving standard treatment within the EpSSG MTS 2008 protocol. Patients and Methods Previously untreated patients aged < 21 years with MTS RMS received standard induction chemotherapy with radiotherapy (RT) and/or surgery to the primary site and RT recommended to all metastatic sites. Clinical characteristics, treatment and outcomes of patients with lung-only MTS RMS were compared to lung + other site and other site MTS RMS. Results Among 270 patients with MTS RMS, 59 (22%) had lung-only metastatic disease, 68 (25%) in lung + other and 143 (53%) in other sites. 3-yr Event Free Survival (EFS) and Overall Survival (OS) for lung-only MTS RMS were 40% (95%CI 27-53%) and 60% (95%CI 46-71%). Although 3-yr OS for lung-only MTS RMS was significantly better than lung + other (35%; 95% CI 24-47%) and other (49%; 95% CI 40-57%) sites (p = 0.0382), EFS and OS adjusted for known clinical (Oberlin) risk factors, did not differ between the groups. 3-year EFS was significantly higher in patients with lung-only MTS who received RT to the lungs (RT, n=26, EFS 56%, 95% CI 35-73%; no RT, n=24, EFS 33%, 95% CI 16-52%, p=0.0435). Conclusions Better outcomes for lung-only MTS RMS seem to be determined by the presence of fewer clinical risk factors. Whole lung radiotherapy continues to be recommended in patients with lung-only MTS RMS.
No takes yet. Share an insight, caveat, or question.
Chisholm et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: